共 43 条
- [31] Validity of CA-125 elimination rate constant K for indicating prognosis and therapeutic selection among Japanese patients with high-grade serous ovarian carcinoma: a single-center retrospective studyINTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_3) : A53 - A53Kochi, YukiNoguchi, DaitoOsone, FumimasaHosoya, SatoshiTabata, JunyaKuroda, TakafumiNagata, ChieSaito, MotoakiYanaihara, NozomuTanabe, HiroshiTakano, HirokuniYamada, KyosukeOkamoto, Aikou
- [32] Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trialGYNECOLOGIC ONCOLOGY, 2012, 124 (03) : 563 - 568Randall, Leslie M.Sill, Michael W.Burger, Robert A.Monk, Bradley J.Buening, BarbaraSorosky, Joel I.
- [34] Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase InhibitorJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (11) : 1301 - 1310Tjokrowidjaja, AngelinaFriedlander, M. L.Ledermann, Jonathan A.Coleman, Robert L.Mirza, Mansoor R.Matulonis, Ursula A.Pujade-Lauraine, EricLord, Sarah J.Scott, Clare L.Goble, SandraYork, WhitneyLee, Chee K.
- [35] Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trialANNALS OF ONCOLOGY, 2020, 31 : S614 - S614Colombo, N.Gantzer, J.Ataseven, B.Cropet, C.Scambia, G.Herrero, A.Sevelda, P.Kobayashi, H.Vuylsteke, P.Mirza, M. R.Priou, F.Buderath, P.Pisano, C.Lainez, N.Guillemet, C.Burges, A.Sverdlin, R.El-Balat, A.Raban, N.Ray-Coquard, I. L.
- [36] A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy/safety of farletuzumab in combination with carboplatin plus paclitaxel or carboplatin plus pegylated liposomal doxorubicin (PLD) in women with low CA-125 platinum-sensitive ovarian cancerGYNECOLOGIC ONCOLOGY, 2021, 162 : S38 - S39Herzog, ThomasPignata, SandroGhamande, SharadRubio, Maria-JesusFujiwara, KeiichiVulsteke, ChristofArmstrong, DeborahSehouli, JalidColeman, RobertGabra, HaniScambia, GiovanniMonk, BradleyArija, Jose AngelUshijima, KimioHanna, RabbieZamagni, ClaudioWenham, RobertGonzalez-Martin, AntonioSlomovitz, BrianJia, YanRamsay, LisaTewari, KrishnansuWeil, SusanVergote, Ignace
- [37] Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4NATURE COMMUNICATIONS, 2023, 14 (01)Kim, Yoo-NaPark, BoramKim, Jae WeonKim, Byoung GieKim, Sang WunKim, Hee SeungChoi, Chel HunLim, Myong CheolNgoi, Natalie Y. L.Tan, David S. P.Lee, Jung-Yun
- [38] A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trialJOURNAL OF GYNECOLOGIC ONCOLOGY, 2022, 33 (02)Park, JunsikLim, Myong CheolLee, Jae-KwanJeong, Dae HoonKim, Se IkChoi, Min ChulKim, Byoung-GieLee, Jung-Yun
- [39] Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4Nature Communications, 14Yoo-Na KimBoram ParkJae Weon KimByoung Gie KimSang Wun KimHee Seung KimChel Hun ChoiMyong Cheol LimNatalie YL NgoiDavid SP TanJung-Yun Lee
- [40] EXPLORING THE IMPACT OF RADIOGRAPHIC PROGRESSIVE DISEASE AND FIRST SUBSEQUENT THERAPY ON HEALTH STATE UTILITY VALUES IN GERMLINE-BRCA-MUTATED (GBRCAM) PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER (PSROC) PATIENTS ON OLAPARIB TABLETS AS MAINTENANCE MONOTHERAPYVALUE IN HEALTH, 2018, 21 : S73 - S73Sackeyfio, A.Santi, IFriedlander, M.